Intellia Therapeutics Shares Plunge Following FDA Clinical Hold
28.11.2025 - 08:51:04 | boerse-global.de
A severe clinical setback has struck Intellia Therapeutics, sending its stock value tumbling after the U.S. Food and Drug Administration (FDA) imposed a full stop on its pivotal programs. This regulatory action was triggered by a patient death reported in a key Phase 3 trial, creating immense uncertainty for investors regarding the safety of the company’s technology and the future of its lead drug candidate.
The immediate cause for the stock’s decline is an FDA-mandated “Clinical Hold” on the MAGNITUDE studies for the investigational drug, Nex-z. The hold was instituted following a serious adverse event report detailing a patient fatality linked to acute liver failure accompanied by Read more...
Hol dir den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen - Dreimal die Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt kostenlos anmelden
Jetzt abonnieren.
